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Background: Insulin-like growth factor I (IGF-I) can induce epithelial mesenchymal transition (EMT) in many
epithelial tumors; however, the molecular mechanism by which this occurs is not clearly understood. Additionally,
little is known about the involvement of IGF-I in gastric cancer.
Methods: Two gastric cancer cell lines were treated with IGF-I to induce EMT and levels of transcription factor ZEB2
and microRNA-200c (miR-200c) were measured. Cells were treated with Akt/ERK inhibitors to investigate the role of
these pathways in IGF-I-mediated EMT. Transfection of shRNA plasmids was used to silence the ubiquitin ligase Cbl-b
to assess its involvement in this process. The relationship between IGF-IR and Cbl-b expression, and the effect of IGF-IR
and Cbl-b on metastasis were analyzed in primary gastric adenocarcinoma patients.
Results: IGF-I-induced gastric cancer cell EMT was accompanied by ZEB2 up-regulation. Furthermore, both Akt/
ERK inhibitors and knockdown of Akt/ERK gene reversed IGF-I-induced ZEB2 up-regulation and EMT through
up-regulation of miR-200c, suggesting the involvement of an Akt/ERK-miR-200c-ZEB2 axis in IGF-I-induced EMT.
The ubiquitin ligase Cbl-b also ubiquitinated and degraded IGF-IR and inhibited the Akt/ERK-miR-200c-ZEB2 axis,
leading to the repression of IGF-I-induced EMT. There was a significant negative correlation between the expression of
IGF-IR and Cbl-b in gastric cancer patient tissues (r = -0.265, p < 0.05). More of patients with IGF-IR-positive expression
and Cbl-b-negative expression were with lymph node metastasis (p < 0.001).
Conclusions: Together, these findings demonstrate that the ubiquitin ligase Cbl-b represses IGF-I-induced EMT, likely
through targeting IGF-IR for degradation and further inhibiting the Akt/ERK-miR-200c-ZEB2 axis in gastric cancer cells.
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Gastric cancer is one of the most common causes of cancer
death worldwide [1]. Additionally, most patients are diag-
nosed with advanced metastatic disease; the 5-year survival
rate is approximately 10–15% [2]. Although chemotherapy,
radiotherapy, and targeted therapy have improved the
response rate, patients with metastatic gastric cancer
remain have a poor prognosis [2,3]. Contributing to this
problem is the lack of effective biomarkers for metastasis* Correspondence: cmuliuyunpeng@hotmail.com; qu_xiujuan@hotmail.com
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unless otherwise stated.prediction. Therefore, it is necessary and urgent to explore
the mechanisms of metastasis in gastric cancer.
Tumor metastasis is a multi-step dynamic process involv-
ing multiple factors and genes. Recent evidence indicates
that epithelial-to-mesenchymal transition (EMT) is a key
driver of progression and metastasis in tumors, including
gastric cancer, breast cancer, hepatocellular carcinoma, and
prostate cancer [4-7]. In this process, epithelial cells lose
cell-cell adhesions and acquire properties of mesenchymal
cells, namely enhanced migratory and invasive abilities
[8]. Many growth factors are involved in the initiation of
EMT, including the insulin-like growth factor-I receptor
(IGF-IR)/ligand system that has been reported to increase
the metastatic potential of prostate and breast cancer cellshis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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baseline IGF-I serum levels in patients with gastric cancer
and overexpression of IGF-IR is a significant predictive
value for poor survival in such patients [9,10]. However,
whether IGF-I promotes gastric cancer metastasis by
EMT, and the mechanisms by which this may occur
remain unclear.
Ubiquitination is a post-translational modification that
targets cellular proteins for degradation [11]. Almost all
cellular processes are regulated by the ubiquitin prote-
asome system, including EMT [12]. Cbl-b is the second
member of the E3 ubiquitin ligase Cbl family, and our
group and others have revealed that Cbl-b regulates
cancer cell proliferation, drug sensitivity, and migration
[13-15]. Knock-down of Cbl-b enhances epidermal growth
factor-induced disruption of human mammary epithelial
cell adherens junctions (AJs) and cell motility [16]. The
inducible up-regulation of c-Cbl and Cbl-b affects cell
adhesion through regulation of the adhesion-related
kinases Pyk2 and Paxillin in HL-60 cell differentiation
[17]. Moreover, Cbl-b can also degrade the IGF-I sig-
naling intermediate IRS-1 and reduce protein synthesis
in unloading-induced muscle atrophy [18]. Our recent
published data demonstrated that Cbl-b suppressed
TRAIL-induced IGF-IR activation by regulating its distri-
bution in the lipid raft [19]. However, whether Cbl-b can
target IGF-IR for degradation and if this process is involved
in IGF-I-induced EMT require further investigations.
Here, we reveal the existence of an Akt/ERK-miR-
200c-ZEB2 axis in IGF-I-induced EMT in gastric cancer
cells. Furthermore, the ubiquitin ligase Cbl-b ubiquiti-
nated IGF-IR and repressed IGF-I-induced EMT through
negative regulation of this Akt/ERK-miR-200c-ZEB2 axis.
Materials and methods
Cell cultures
Human gastric cell lines MGC803, SGC-7901 were ob-
tained from the Type Culture Collection of the Chinese
Academy of Sciences (China). The cells were maintained
in RPMI-1640 medium (Gibco) with 10% heat-inactivated
fetal bovine serum (FBS), penicillin (100 U/mL) and
streptomycin (100 mg/mL) in an atmosphere of 95% air
and 5% CO2 at 37°C. The cells were sub-cultured every 2–
3 days and harvested in their logarithmic phase of growth.
Reagents and antibodies
Recombinant human IGF-I was purchased from R&D
System (Wiesbaden, Germany). The dual IGF-IR/IR in-
hibitor OSI-906 was purchased from SelleckBio (USA).
Specific PI3K/Akt inhibitor LY294002 was purchased
from Sigma (St. Louis, MO), and specific ERK1/2 inhibitor
PD98059 was purchased from Promega (Madison, WI).
Proteasome inhibitor bortezomib (PS-341) was purchased
from Millenium Pharmaceuticals Inc (Cambridge, MA,USA). Anti-E-cadherin, anti-Vimentin, anti-ZEB1, anti-
IGF-IR, anti-phospho-IGF-IR (Tyr1131), anti-phospho-
GSK-3β, anti-GSK-3β and anti-phospho-P53 (Ser15)
were purchased from Cell Signaling Technology (Beverly,
MA). Anti-Snail and anti-Twist2 were purchased from
Abcam (Cambridge, MA). All the other antibodies were
purchased from Santa Cruz Biotechnology (USA).
Patients and tissue samples
A total of 50 lymph node metastasis and 50 non-lymph
node metastasis surgically resected primary gastric adeno-
carcinoma patient specimens were obtained from the First
Hospital of China Medical University between Jan 1st
2007 and Dec 31st 2008. Age, sex, pTNM stage and
Lauren grade were evaluated following medical charts and
pathology records. pTNM stage was examined according
to the 7th edition of AJCC cancer staging manual. Lauren
grade was reference to WHO classification. No patients
had received any neoadjuvant chemotherapy and radio-
therapy. All research involving human participants were
approved by the Ethics Committee of China Medical
University. Written informed consents were obtained
from all the participants in accordance with the Helsinki
Declaration.
Immunohistochemistry
One hundred of formalin-fixed, paraffin-embedded primary
gastric cancer tissues were cut into 3-mm sections. All
sections were de-paraffinized in xylene and dehydrated
through a graduated alcohol series followed by the
standard procedure for the S-P immunohistochemical
kit (Fuzhou Maixin Biological Technology Ltd., Fujian,
China). Sections were incubated with anti-Cbl-b or
anti-IGF-IR in PBS at 4°C overnight in a moist box. 3,
30-diamino-benzidine tetrahydrochloride (DAB kit; Fuzhou
Maixin Biological Technology Ltd., Fujian, China) was
used for immune complex visualization. The staining
was evaluated by scanning the entire tissue specimen
under low magnification (×10) and confirmed under high
magnification (×20 and × 40). The protein expression
was visualized and classified based on the percentage of
positive cells and the intensity of staining. Tumors with
less than 10% Cbl-b or IGF-IR expression were regarded as
negative. Immunostaining was considered as positive when
more than 10% of the neoplastic cells were stained. Final
scores were assigned by two independent pathologists.
Western blot and immunoprecipitation assay
Western blot analysis was performed as described in our
previous studies [15]. Briefly, samples were solubilized
in 1% Triton lysis buffer on ice or in RIPA buffer. For
immunoprecipitation, the collected cell lysates were
incubated with the indicated antibodies (1–4 μg) or
immunoglobulin-G (Cell Signaling Technology, Beverly,
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4°C. On the other day, the immunoprecipitates were
washed extensively with lysis buffer for four times. For
the preparation of total cell lysates, the monolayers were
lysed directly as described in western blot analysis.
Both immunoprecipitated proteins and cell lysates
were then eluted by boiling water at 100°C for 5 min
with 3 × sampling buffer. Total proteins were subjected
to SDS-polyacrylamide gel electrophoresis and elec-
tronically transferred to nitrocellulose membranes. After
blocking with 5% skim milk in TBST buffer, the blots
were incubated in the primary antibodies followed by
secondary antibodies as indicated time. Proteins were
detected using an enhanced chemiluminescence reagent
(SuperSignal Western Pico Chemiluminescent Substrate;
Pierce, USA). The final result was analyzed by NIH Image
J software.Reverse-transcription-polymerase chain reaction (RT-PCR)
The cells were cultured and harvested at the indicated
times. Total RNA was isolated with the RNeasy mini kit
(Qiagen, Carlsbad, CA, USA). RT-PCR was performed with
primer pairs for ZEB2: forward (5′-CGCTTGACATCACT
GAAGGA-3′) and reverse (5′-CTTGCCACACTC TGTG
CATT-3′). For actin as control: forward (5′-GTGGGG CG
CCCCAGGCACCA-3′) and reverse (5′-CTCCTTAATGT
CACGCACGATTTC- 3′). PCR conditions were 95°C
for 5 min; 31 cycles of 95°C for 30 s, 55°C for 45 s,
72°C for 40 s; one cycle of 72°C for 10 min. Then the
amplified products were separated on 1.5% agarose
gels, and stained with ethidium bromide and visualized
under UV illumination.Quantitative reverse transcription real-time PCR (qRT-PCR)
Total RNA was extracted as mentioned above. For
microRNAs, The One Step PrimeScript® miRNA cDNA
Synthesis Kit (Takara, Japan) was used for RNA reverse
transcription. Relative expression of microRNA was cal-
culated via the comparative cycle threshold (Ct) method,
and the expression of U6 small nuclear RNA was used
as reference. The sequence-specific forward primers for
mature miR-200c was: 5′-ACACTCCAGCTGGGTAAT
ACTG CCGGGTAA-3′ and for U6 internal control was:
forward (5′-GCTTCGGCAGCACATAT ACTAAAAT-3′)
and reverse (5′-CGCTTCACGAATTTGCGTGTCAT-3′),
respectively. The Uni-miR qPCR Primer was included in
the kit. SYBR® Premix Ex Taq™ II (Perfect Real Time)
(Takara, Japan) was used for monitoring the amount of
miRNA. The PCR conditions were 30 s at 95°C, followed
by 45 cycles at 95°C for 5 s and 58°C for 25 s. The thresh-
old cycle and 2-ΔΔCt method were used for calculating the
relative amount of the target RNA.MicroRNA microarray
The expression levels of 847 human and 609 mouse
microRNAs were quantitated using a GeneChip miRNA
Array (Affymetrix, Santa Clara, CA) according to the
manufacturer’s instructions by Gene Tech Biotechnol-
ogy Company (Shanghai, China). In brief, total RNA
(1 μg) was extracted with miRNeasy Mini Kit (Qiagen)
and labeled with a FlashTag Biotin RNA Labeling kit
(Genisphere, Hatfield, PA). Then the labeled RNA was
injected onto the microarrays and incubated at 48°C for
16 hours. After washing and staining, the signals were
obtained using a GeneChip Scanner 3000 (Affymetrix,
Santa Clara, CA). Data were normalized using the RMA
algorithm.
Migration assay
Migration assay was performed using Boyden chambers
and polycarbonate inserts with 8-um pore size membranes.
The cells (1 × 104 cells/well) were seeded into the upper
chamber with 200 μL serum-free RPMI 1640 medium with
or without IGF-I (100 ng/mL). Then the upper chamber
was inserted into the lower chamber of 24-well culture
dishes with 500 μL of RPMI 1640 containing 2.5% FBS.
After incubation for 48 hours, the culture media in the
upper chamber and non-migrated cells on the inner side of
the membrane were carefully removed with a cotton swab.
After dried for 1 hour at room temperature, the migrated
cells onto the outer side of the membrane were fixed with
4% formaldehyde for 1 min and stained with 0.1% Giemsa
stain solution for 2 hours. Then the migrated cells were
counted in five different fields at × 10 magnification under
the microscope.
Immunofluorescence
The cells were seeded in Lab-Tek chamber slides (Nunc
S/A, Polylabo, Strasbourg, France). After starved over-
night, the cells were treated with or without IGF-I
(100 ng/mL) for 48 hours and fixed in 3.3% paraformal-
dehyde for 15 min, permeabilized with 0.2% Triton X-
100 for 5 min, blocked with 5% bovine serum albumin
(BSA) for 1 hour and then incubated with anti-E-
cadherin and anti-Vimentin antibody overnight at 4°C.
The next day, Alexa Fluor 546-conjugated goat anti-rabbit
IgG or Alexa Fluor 488-conjugated goat anti-rabbit IgG
(Molecular Probes) were added in blocking solution for
1 hour at room temperature in the dark. 4′6′-diamidino-
2- phenylindole was used to stain nuclei for 5 min. After
mounted with the Slow Fade Antifade Kit (Molecular
Probes, Eugene, OR, USA), the cells were visualized by
fluorescence microscopy (BX61, Olympus, Japan).
Small interfering RNA transfections
Cells were seeded at a density of 3 × 105 cells/well in
6-well plates. The cells were transfected with siRNAs
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USA) following the manufacturer’s instructions. Two
siRNA sequences (Qiagen Inc., Valencia, CA) each for
ERK1 and ERK2 were as follows: ERK1: 5′-CGUCUAA
UAUAUAAAUAUA dTdT-3′ (sense), 5′-UAUAUUUAU
AUAUUAGACGdGdG-3′ (antisense); ERK2: 5′-CACU U
GUCAAGAAGCGUUAdTdT-3′ (sense), 55′-UAACGCU
UCUUGACAAGUGdTdT-3′ (anti-sense). The Akt siRNA
was obtained from Sigma (MO, USA) and siRNA sequence
was: 5′-GAGACUGACACCAGGUAUUdT dT-3′ (sense),
5′-AAUACCUGGUGUCAGUCUCdT dT-3′ (anti-sense).
The control sequence was: AATTCTCCGAACGTGT
CACGT. Western blot analysis was used to verify gene-
silencing efficiency.
Plasmid construction and stable cell lines establishment
The method of plasmid construction is performed as
described previously [20].
Statistical analysis
All the presented data were expressed as the mean ± SD
and representative results were from at least three inde-
pendent experiments. Statistical comparisons were cal-
culated by Student’s two-tailed t-test. The correlation
between Cbl-b and IGF-IR expression was assessed using
Spearman rank correlation for continuous variables. TheFigure 1 IGF-I induced EMT and enhanced the migration ability in ga
overnight and then treated with or without 100 ng/mL of IGF-I for 48 h. (A
with antibodies to E-cadherin (green), Vimentin (red), and nuclei was staine
fluorescence microscopy at × 40 magnification. (C) Cell lysates were collected
the Boyden chamber methods as described in Materials and methods. Data a
IGF-I treated, p < 0.05; E-cad, E-cadherin; Vim, Vimentin.effect of Cbl-b and IGF-IR on metastasis was analyzed by
Fisher exact test for tables. p < 0.05 was considered statisti-
cally significant. Statistical analysis was carried out using
SPSS 18.0 software package (SPSS, Inc., Chicago, IL, USA).
Results
IGF-I-induced EMT in gastric cancer cells
To elucidate the effect of IGF-I on human gastric cancer
cells, cultured MGC-803 and SGC-7901 cells were treated
with recombinant IGF-I (100 ng/mL) for 48 h according
to previous study [6]. Figure 1A depicted the dramatic
morphological change associated with IGF-I treatment,
from characteristic epithelial cells with tight junctions
to elongated and spindle-shaped mesenchymal cells.
Following IGF-I treatment, immunofluorescence staining
detected that the distribution of mesenchymal marker
Vimentin was polarized with aggregation at the edges
of the cells compared to a network throughout the cell
cytoplasm in the control group (Figure 1B). Significant
down-regulation of the epithelial marker E-cadherin,
and up-regulation of Vimentin and transcription factor
ZEB2 were revealed under western blotting analysis
(Figure 1C). Additionally, IGF-I treatment enhanced
cellular migration, with 78 ± 1.5% treated MGC-803
cells vs. 26 ± 4.0% control cells undergoing migration.
Similar findings were made in SGC-7901 cells (p < 0.05;stric cancer cells. MGC-803 and SGC-7901 cells were serum-starved
) Photos were taken at × 20 magnification. (B) The cells were stained
d with 4′,6′-diamidino-2-phenylindole (DAPI). Images were captured by
for Western blot analysis. (D) The migration assays were performed using
re means ± SD in three independent experiments. * IGF-I untreated vs.
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in gastric cancer cells.
IGF-I-induced ZEB2 up-regulation was partially regulated
by Akt/ERK pathways
Following IGF-I treatment, transient phosphorylation of
IGF-IR, Akt, and ERK was detected at 3 min, with recov-
ery to baseline levels after 6 h. Increase in GSK-3β (Ser9)
phosphorylation was detected after IGF-I stimulation for
3 min in both MGC-803 and SGC-7901 gastric cancer cellFigure 2 IGF-I activated Akt/ERK downstream signaling pathways and
and SGC-7901 cells were incubated with IGF-I (100 ng/mL) for the indicated tim
blot. (B-D) The serum-starved cells were pretreated with or without OSI-906 (1
(100 ng/mL) stimulation for 48 h. Cell lysates were collected for Western blot a
OSI-906; PD, PD98059; LY, LY294002.lines. Furthermore, phosphorylation of P53 (Ser15) was
detected after IGF-I stimulation for 3 min and 30 min
in MGC-803 and SGC-7901 gastric cancer cell lines,
respectively (Figure 2A). Cells pretreated with the IGF-
IR/IR inhibitor OSI-906 (10 μM) for 2 h before IGF-I
stimulation for a further 48 h did not exhibit either mor-
phological changes or epithelial-mesenchymal phenotype
marker switching. Additionally, IGF-I-induced ZEB2 up-
regulation was prevented in cells pretreated with OSI-906
(Figure 2B). Similarly, the PI3K/Akt inhibitor LY294002induced EMT in gastric cancer cells. (A) The serum-starved MGC-803
es, the phosphorylation of IGF-IR, ERK and Akt were analyzed by Western
0 μM), PD98059 (20 μM) or LY294002 (100 μM) for 2 h followed by IGF-I
nalysis. Photos were taken at × 20 magnification. E-cad, E-cadherin; OSI,
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partially suppressed the appearance of IGF-I-induced
EMT and ZEB2 up-regulation (Figure 2C, D). Consistently,
cell morphology and EMT marker expression represented
that IGF-I-induced EMT was also partially reversed after
transient knockdown of ERK or Akt gene in SGC-7901
cells (Additional files 1 and 2). These results indicate that
IGF-I-induced ZEB2 up-regulation is in part due to activa-
tion of the downstream Akt/ERK signaling pathways in
gastric cancer cells.
An Akt/ERK-miR-200c-ZEB2 axis was involved in
IGF-I-induced EMT
ZEB2 expression was increased 48 h after IGF-I treat-
ment (Figure 3A). However, quantitative PCR analysis
showed no change in ZEB2 mRNA levels with or with-
out IGF-I treatment in both MGC-803 and SGC-7901
cells (Figure 3B). Given that miR-200c represses EMT by
targeting ZEB2 [21], we further examined whether the
expression of miR-200c was altered in IGF-I-induced
EMT. The relative level of miR-200c was decreased by
more than 30% in MGC-803 cells and 50% in SGC-7901Figure 3 An Akt/ERK-miR-200c-ZEB2 axis was involved in IGF-induced
serum-starved overnight and then treated with or without 100 ng/mL of IGF-
(B) The level of mRNA for ZEB2 was analyzed by RT-PCR. (C-E) The serum-star
(100 μM) for 2 h followed by IGF-I (100 ng/mL) stimulation for 48 h. The expre
in three independent experiments. * IGF-I untreated vs. IGF-I treated, p < 0.05.cells 48 h following IGF-I treatment (p < 0.05; Figure 3C).
Meanwhile, pretreatment with LY294002 and PD98059
partially reversed miR-200c down-regulation after IGF-I
stimulation (Figure 3D, E). IGF-I-induced miR-200c
decrease was also partially suppressed after transient
knockdown of ERK or Akt gene in SGC-7901 cells
(Additional file 1C, 2C). These results indicate that an
Akt/ERK-miR-200c-ZEB2 axis might be involved in
IGF-I-induced EMT in gastric cancer cells.
Cbl-b repressed IGF-I-induced EMT in gastric cancer cells
Previous study has shown that the Cbl-transforming vari-
ant (70z-Cbl) can induce a cascade of molecular alterations
leading to EMT [22]. To investigate the effect of Cbl-b on
maintaining the epithelial phenotype, shRNA plasmids
targeting Cbl-b and non-silencing control plasmids
were stably transfected into MGC803 cells. After G418
selection, stable transfectants with Cbl-b expression levels
of less than 10% that of endogenous Cbl-b were used in
subsequent experiments (Figure 4A). Interestingly, Cbl-b
shRNA-transfected (ShRNA Cbl-b) cells lost typical epithe-
lial-like morphology, with acquisition of EMT features.EMT in gastric cancer cells. MGC-803 and SGC-7901 cells were
I for 48 h. (A) The expression of ZEB2 was analyzed by Western blot.
ved cells were pretreated with or without PD98059 (20 μM) or LY294002
ssion of miR-200c was analyzed by real-time PCR. Data are means ± SD
Control group as reference. PD, PD98059; LY, LY294002.
Figure 4 Cbl-b repressed IGF-I-induced EMT in gastric cancer cells. (A) Knockdown effect of Cbl-b was examined by Western blot. (B) The
serum-starved cells were treated with or without IGF-I for 48 h. Photos were taken at × 20 magnification. (C) Immunofluorescent staining was performed
as described above and visualized by fluorescence microscope at × 40 magnification. (D) Cell lysates were collected for Western blot analysis. (E) The
migration assay was performed using the Boyden chamber methods as described in Materials and methods. Data are means ± SD in three independent
experiments. * IGF-I untreated vs. IGF-I treated, p < 0.05; ** In IGF-I untreated group, ShRNA Cbl-b vs. NS Control, p < 0.05; *** In IGF-I treated group,
ShRNA Cbl-b vs. NS Control, p < 0.05. E-cad, E-cadherin; Vim, Vimentin; ShRNA Cbl-b, Cbl-b shRNA transfected; NS Control, Non-silencing controls.
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mesenchymal-like morphology with elongation of the cell
shape and cell scattering (Figure 4B). Immunofluorescence
detected down-regulation of E-cadherin and up-regulation
of Vimentin in Cbl-b knockdown cells when compared
with the non-silencing controls (NS Control; Figure 4C).
Down-regulation of E-cadherin and up-regulation ofVimentin and ZEB2 were also observed in ShRNA Cbl-b
cells in the absence or presence of IGF-I stimulation
(Figure 4D). Knockdown of Cbl-b expression enhanced
cell migration compared with NS control cells, especially
after IGF-I stimulation (Figure 4E). Together, these data
suggest that Cbl-b represses IGF-I-induced EMT and
maintains the epithelial phenotype in gastric cancer cells.
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inhibiting the Akt/ERK- miR-200c-ZEB2 axis
To understand the effect of Cbl-b on Akt/ERK-miR-
200c-ZEB2 axis, the activation of Akt/ERK downstream
pathways was examined. As shown in Figure 5A, knock-
down of Cbl-b prolonged the length of time for Akt and
ERK phosphorylation. Additionally, quantitative real-time
PCR and microRNA array revealed that the relative level
of miR-200c was decreased by 70% and 50% in shRNA
Cbl-b cells compared with NS control cells, respectively
(Figure 5B, C). These data suggest a role for Cbl-b inFigure 5 Cbl-b sustained the epithelial phenotype through inhibiting
serum-starved cells were treated with or without IGF-I for indicated times,
of miR-200c was analyzed by real-time PCR. (C) The expression of miR-200c
methods. Data are means ± SD in three independent experiments. Control
Cbl-b, Cbl-b shRNA transfected; NS Control, Non-silencing controls.sustaining the epithelial phenotype via inhibiting the
Akt/ERK-miR-200c-ZEB2 axis in gastric cancer cells.
Cbl-b inhibited IGF-I-induced EMT by degradation of
IGF-IR through the ubiquitin-proteasome pathway
Degradation of IGF-IR protein was observed 48 h after
IGF-I treatment in two gastric cancer cell lines (Figure 1C).
It has been reported that receptor tyrosine kinases are
degraded by receptor ubiquitination, accelerated endocyto-
sis, and lysosome or proteasomal-dependent degradation
[23]. To investigate whether the ubiquitin- proteasomeAkt/ERK-miR- 200c-ZEB2 axis in gastric cancer cell. (A) The
cell lysates were collected for Western blot analysis. (B) The expression
was performed using microRNA array as described in Materials and
group as reference. * ShRNA Cbl-b vs. NS Control, p < 0.05. ShRNA
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803 cells were pretreated with the proteasome inhibitor
PS341 (5 nM) for 12 h followed by IGF-I stimulation.
IGF-IR degradation was dramatically prevented in these
cells (Figure 6A). Given that c-Cbl has an important
role in IGF-IR ubiquitination in human osteosarcoma
cell lines [24], we next assessed whether Cbl-b could
mediate IGF-IR ubiquitination in gastric cancer cells.
Cbl-b was associated with IGF-IR 1 h after IGF-I treat-
ment in MGC-803 cells (Figure 6B). A clear increase in
ubiquitinated IGF-IR was present 6 h after IGF-I treatment
of MGC-803 cells with a peak level reached at 12 h
(Figure 6C). This suggested that IGF-I-induced degradation
of IGF-IR was dependent on the ubiquitin-proteasome
pathway. Furthermore, knockdown of Cbl-b effectively
inhibited ubiquitination of IGF-IR compared with the NS
control (Figure 6D). Taken together these findings indicate
that Cbl-b suppresses IGF-I-induced EMT by ubiquitina-
tion and degradation of IGF-IR in gastric cancer cells.
Association between IGF-IR and Cbl-b expression in
gastric cancer tissues
IGF-IR and Cbl-b expressions were detected using immu-
nohistochemical analysis. Out of 100 gastric adenocar-Figure 6 Ubiquitin ligase Cbl-b ubiquitinated and degradated IGF-IR
MGC-803 cell was pretreated with or without PS341 (5 nM) for 12 hours an
IGF-IR was analyzed by western blot. (B) The cell was treated with IGF-I for
Cbl-b and IGF-IR were analyzed by western blot. (C-D) The serum-starved M
indicated times. IGF-IR was immunoprecipitated and ubiquitin was analyze
Non-silencing controls.cinoma samples, 69% (69/100) showed IGF-IR positive
staining and 58% (58/100) of patients had Cbl-b positive
expression. Importantly, there was a significant negative
correlation between the expression of IGF-IR and Cbl-b
(r = -0.265, p < 0.05) (Table 1). Figure 7A (a-f) showed two
representative patients sections of IGF-IR/Cbl-b expres-
sion and HE staining. Correlations between the expression
of IGF-IR or Cbl-b and the clinicopathological factors
were analyzed. As shown in Table 2, more of gastric
cancer patients expressing IGF-IR were at late-stage
pTNM (p < 0.001) and examined with lymph node metas-
tasis (p < 0.001). On the contrary, patients with Cbl-b
expression were more likely to be at early-stage pTNM
(p < 0.001) and examined without lymph node metastasis
(p < 0.001). However, no associations were found between
IGF-IR or Cbl-b expression and age, gender or Lauren
grade.
Discussion
The IGF-I/IGF-IR signaling pathway has been reported
to induce EMT through activation of the MEK/MAPK and
PI3K/Akt pathways in immortalized mammary epithelial,
breast, and prostate cancer cells [5,6,25,26]. Furthermore,
increased expression of the transcription factor ZEB1 isprotein after IGF-I treatment in MGC-803 cell. The serum-starved
d then incubated with IGF-I for indicated times. (A) The expression of
indicated times before immunoprecipitation with anti-Cbl-b antibody,
GC-803, ShRNA Cbl-b and NS Control cells were treated with IGF-I for
d by western blot. ShRNACbl-b, Cbl-b shRNA transfected; NS Control,
Table 1 Spearman’s correlations between Cbl-b expression and IGF-IRexpression in primary gastric cancer patients
Cbl-b expression Number (%) IGF-IR expression Spearman’s rP value
Negative (%) Positive (%)
Negative (%) 42 (42%) 8 (19.0) 34 (81.0) -0.265 0.008*
Positive (%) 58 (58%) 23 (39.7) 35 (60.3)
Number (%) 100 31 (31%) 69 (69%)
*P < 0.05.
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http://www.molecular-cancer.com/content/13/1/136essential for IGF-I-induced EMT [6]. However, whether
IGF-I can induce gastric cancer cell EMT or up-regulate
expression of ZEB2, another ZEB transcription factor
family member, is unknown. Here, we demonstrated that
IGF-I initiated EMT in gastric cancer cells and increased
their migration potential through up-regulation of ZEB2.Figure 7 Representative images for IGF-IR and Cbl-b immunohistochem
staining. The tumor is composed of atypical cells and irregularly shaped tubu
cytoplasm (in brown). (c, e) IGF-IR and Cbl-b negative staining (-). The origina
EMT. In gastric cancer cells, IGF-I binds to its receptor IGF-IR and activates Akt/
up-regulates E-cadherin repressor ZEB2 and down-regulates miR-200c. There
required for sustaining the epithelial phenotype probably through targeting IG
IGF-I-induced EMT.This process was at least partially dependent on Akt/ERK
downstream signaling pathways, which were upstream
factors of ZEB2 activation in gastric cancer cells in vitro.
ZEB2 is an important transcriptional factor in EMT
and functions as a metastasis regulator via direct binding
to the promoter site of the cell adhesion molecule E-ical staining in three serial sections from two cases. (A) (a, d) HE
les. (b, f) IGF-IR and Cbl-b positive staining (+) in cell membrane and
l magnification is 100×. (B) Working model for Cbl-b in IGF-I-induced
ERK downstream signaling pathways. The activation of signal pathways
is an Akt/ERK-miR-200c-ZEB2 axis in the process. Ubiquitin ligase Cbl-b is
F-IR for degradation and further inhibiting Akt/ERK-miR-200c-ZEB2 axis in
Table 2 Correlation between the expression of IGF-IR or Cbl-b and the clinicopathological factors in primary gastric
cancer patients
Factors All cases IGF-IR Cbl-b
Negative (%) Positive (%) P value Negative (%) Positive (%) P value
Agea
< 59 46 15 (32.6) 31 (67.4) 0.749 22 (47.8) 24 (52.2) 0.278
≥ 60 54 16 (29.6) 38 (70.4) 20 (37.0) 34 (63.0)
Gender
Male 72 22 (30.6) 50 (69.4) 0.878 31 (43.1) 41 (56.9) 0.733
Female 28 9 (32.1) 19 (67.9) 11 (39.2) 17 (60.8)
pTNM stage
I + II 46 24 (52.2) 22 (47.8) <0.001* 6 (13.0) 40 (87.0) <0.001*
III + IV 54 7 (13.0) 47 (87.0) 36 (66.7) 18 (33.3)
Lymph node metastasis
Absent 50 26 (52.0) 24 (48.0) <0.001* 6 (12.0) 44 (88.0) <0.001*
Present 50 5 (10.0) 45 (40.0) 36 (72.0) 14 (28.0)
Lauren grade
Intestinal 22 8 (36.4) 14 (63.6) 0.614 7 (31.8) 15 (68.2) 0.452
Diffuse 46 12 (26.1) 34 (73.9) 22 (47.8) 24 (52.2)
mixed 32 11 (34.4) 21 (65.6) 13 (40.6) 19 (59.4)
aMean age.
*P <0.05.
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http://www.molecular-cancer.com/content/13/1/136cadherin in several cancer types [27-29]. Previous studies
have identified that an increased ZEB2/E-cadherin ratio
positively correlates with invasive disease and poor
prognosis in breast and ovarian cancers [30]. Here, we
observed that ZEB2 protein levels were up-regulated
after IGF-I treatment without an increase in ZEB2 mRNA,
suggesting that IGF-I-induced ZEB2 up-regulation might
be post-transcriptionally regulated. Recent studies have
shown that reduced levels of MicroRNA-200 (miR-200)
family members are associated with tumor metastasis
and poor disease outcomes [31]. MiR-200c is able to
suppress EMT through targeting of ZEB1/2 in some
tumor cells [32-34]. Furthermore, the existence of an
Akt-miR-200c-E-cadherin axis in the EMT process in
renal cell carcinoma has been identified [35]. Here, we
found reduced expression levels of miR-200c in both
MGC-803 and SGC-7901 gastric cancer cells following
IGF-I stimulation. PI3K/Akt inhibitor LY294002, ERK
inhibitor PD98059 and transient knockdown of ERK or
Akt gene partially reversed the down-regulation of
miR-200c by IGF-I. These results support the existence
of an Akt/ERK-miR-200c-ZEB2 axis in IGF-induced
EMT in gastric cancer cells.
Cbl ubiquitin ligase is reported to maintain AJ dynam-
ics and suppress cell migration through down-regulation
of epidermal growth factor receptor-Vav2 signaling in
human mammary epithelial cells [16]. Additionally, expres-
sion of 70z-Cbl in Madin-Darby canine kidney epithelialcells results in breakdown of cell-cell junctions in a manner
characteristic of EMT [22]. Our previous study reported
that up-regulation of c-Cbl and Cbl-b was involved in
all-trans retinoic acid and bufalin-induced cell adhesion in
human promyelocytic cells [17]. This new report revealed
that knockdown of Cbl-b facilitated the initiation and
progression of EMT in MGC-803 cells. Meanwhile, IGF-
induced EMT and migration potential were increased in
Cbl-b-knockdown cells. This process was accompanied by
prolonged activation time for the Akt/ERK downstream
signaling pathways, inhibition of miRNA-200c expression,
and up-regulation of the transcriptional repressor ZEB2.
Our microRNA array and real-time PCR data reveal a
decreased expression level of miRNA-200c in Cbl-b knock-
down cells. Together, these findings suggested that
Cbl-b repressed IGF-I-induced EMT and migration
ability through negative regulation of the Akt/ERK-
miR-200c-ZEB2 axis.
To understand how exactly Cbl-b regulated the Akt/
ERK-miR-200c-ZEB2 axis in IGF-I-induced EMT, we
further investigated the relationship between the Cbl-b
and IGF-IR signaling pathways. We found that IGF-IR
was first phosphorylated and degraded by IGF-I through
the proteasome system. Phosphorylation is the premise
of ubiquitination. Phosphorylation of the substrate makes
proteins more susceptible to be recognized by the appro-
priate ligase and formed the ligase complex [36]. Previous
study has implicated that EGFR recognition by c-Cbl
Li et al. Molecular Cancer 2014, 13:136 Page 12 of 13
http://www.molecular-cancer.com/content/13/1/136probably depends on the phosphorylation of a specific
receptor tyrosine residue [37]. Consistently, a recent study
has reported that c-Cbl combines with IGF-IR and medi-
ates receptor polyubiquitination in response to IGF-I
ligand in human osteosarcoma cells [24]. Furthermore,
ubiquitination of activated EGFR by c-Cbl complexes is
involved in ERβ-1-mediated repression of EMT in basal-
like breast cancer cells [38]. In the present study, we found
that IGF-IR combined with Cbl-b and initiated IGF-IR
ubiquitination after IGF-IR phosphorylation and activation
in MGC-803 gastric cancer cells. Combination with Cbl-b
initiated receptor degradation of IGF-IR following IGF-I
stimulation. Knockdown of Cbl-b significantly inhibited
this process. These results suggest that Cbl-b likely ubiqui-
tinates and degrades IGF-IR, and that this is necessary to
repress the Akt/ERK-miR-200c-ZEB2 axis and the process
of IGF-I-induced EMT. By examining 100 clinical gastric
adenocarcinoma tissues, we found that IGF-IR positive
expression was significantly associated with late-stage
pTNM and positive lymph node metastasis, which was
consistent with previous reports [10]. More importantly,
the expression of IGF-IR was negatively correlated with
the expression of Cbl-b. Cbl-b positive expression was
associated with early-stage pTNM and negative lymph
node metastasis. These newly reported results further
strengthened the possibility that Cbl-b could repress
IGF-IR and decrease the risk of developing lymph node
metastasis in patients with gastric cancer.Conclusions
These findings indicate that IGF-I induces EMT and
increases migration ability in gastric cancer cell lines.
Furthermore, an Akt/ERK-miR-200c- ZEB2 axis is involved
in this process. Cbl-b functions as a crucial repressor
in IGF-I-induced EMT through the degradation of
IGF-IR and inhibition of the Akt/ERK-miR-200c-ZEB2
axis (Figure 7B). Cbl-b expression is negatively correlated
with IGF-IR expression in clinical gastric cancer sample.
These results warrant further investigation of the associ-
ation between the IGF-IR signaling pathway and gastric
cancer metastasis. Last, Cbl-b could also serve as a clinical
biomarker to identify gastric cancer patients with a lower
risk of developing metastasis.Additional files
Additional file 1: Knockdown of ERK reversed IGF-I-induced EMT
and decreased level of miRNA-200c. (A-B) The serum-starved cells were
transfected with Scramble Control siRNA or ERK siRNA followed by IGF-I
(100 ng/mL) stimulation for 48 h. Cell lysates were collected for Western
blot analysis. Photos were taken at × 20 magnification. (C) The expression
of miR-200c was analyzed by real-time PCR. Data are means ± SD in three
independent experiments. * IGF-I untreated vs. IGF-I treated, p < 0.05.
Control group as reference. E-cad, E-cadherin.Additional file 2: Knockdown of Akt reversed IGF-I-induced EMT
and decreased level of miRNA-200c. (A-B) The serum-starved cells were
transfected with Scramble Control siRNA or Akt siRNA followed by IGF-I
(100 ng/mL) stimulation for 48 h. Cell lysates were collected for Western
blot analysis. Photos were taken at × 20 magnification. (C) The expression
of miR-200c was analyzed by real-time PCR. Data are means ± SD in three
independent experiments. * IGF-I untreated vs. IGF-I treated, p < 0.05.
Control group as reference. E-cad, E-cadherin.
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